99 HIGH STREET, 30TH FLOOR, BOSTON, MA
Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Amended material disclosure
Megan Sniecinski Appointed Chief Operating Officer at Praxis Precision Medicines
Praxis Precision Medicines, Inc. Announces Underwritten Offering of 2.2M Shares
Praxis Precision Medicines Reports Cash and Securities of $925 Million
Other Events
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership